1. Home
  2. TGE vs THAR Comparison

TGE vs THAR Comparison

Compare TGE & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$1.09

Market Cap

85.8M

ML Signal

N/A

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$2.79

Market Cap

90.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGE
THAR
Founded
2023
2017
Country
France
United States
Employees
N/A
3
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.8M
90.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
TGE
THAR
Price
$1.09
$2.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
160.2K
369.0K
Earning Date
10-20-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$130,212,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.32
N/A
Revenue Growth
316.50
N/A
52 Week Low
$0.78
$0.95
52 Week High
$37.02
$9.08

Technical Indicators

Market Signals
Indicator
TGE
THAR
Relative Strength Index (RSI) N/A 57.51
Support Level N/A $2.20
Resistance Level N/A $2.62
Average True Range (ATR) 0.00 0.19
MACD 0.00 0.06
Stochastic Oscillator 0.00 85.51

Price Performance

Historical Comparison
TGE
THAR

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: